Skip to main content

Advertisement

Table 2 Tumor/normal tissue (T/NT) ratios at 24 h post-injection of 111In- or 64Cu-DOTA-trastuzumab Fab

From: A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT

  T/NT Ratio a, b, c
Tissue 111 In-DOTA-trastuzumab Fab 64 Cu-DOTA-trastuzumab Fab
Blood 9.73 ± 2.46 3.56 ± 0.62
Heart 4.31 ± 0.83 2.09 ± 0.56
Lungs 5.06 ± 1.12 1.03 ± 0.19
Liver 1.27 ± 0.26 0.59 ± 0.16
Kidneys 0.06 ± 0.02 0.09 ± 0.02
Stomach 6.99 ± 2.05 1.48 ± 0.37
Intestines 6.61 ± 1.78 1.05 ± 0.22
Spleen 1.79 ± 0.48 1.00 ± 0.20
Muscle 6.12 ± 3.33 6.78 ± 1.90
  1. 111In- or 64Cu-DOTA-trastuzumab Fab in athymic mice bearing subcutaneous MDA-MB-361 human breast cancer xenografts. aValues shown are mean ± SD (n = 4). bSignificantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for lungs and intestines (both P < 0.001), blood, heart, liver, stomach (all P < 0.01) and spleen (P < 0.05). cNot significantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for kidneys and muscle (P > 0.05).